News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA's $6.4 Billion Plan for Quick Reviews Moves to Senate


5/21/2012 6:57:34 AM

A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements Mylan Inc. (MYL), Pfizer Inc. (PFE) and other companies struck with regulators wind through Congress. The Senate is set to begin voting as soon as today on more than $2 billion in new fees that drug and device companies will pay regulators through 2017 to review their products for safety and efficacy. The figure includes $1.56 billion from generic- drug companies such as Canonsburg, Pennsylvania-based Mylan, which had been exempt from such review fees.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES